BISPECIFIC ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE

A bispecific monoclonal antibody that specifically binds two distinct epitopes of the Ebola virus (EBOV) glycoprotein (GP) is described. The bispecific antibody is comprised of the antigen binding domains of GP-specific monoclonal antibodies mAb114 and S1-4-A09 ("A09"). The EBOV GP bispeci...

Full description

Saved in:
Bibliographic Details
Main Authors MASCOLA, John R, STRINGHAM, Christopher D, SULLIVAN, Nancy J, PEGU, Amarendra, MISASI, John N, LEIGH, Kendra, ASOKAN, Mangaiarkarasi, BAI, Ke, OLONINIYI, Olamide K, DEMOUTH, Megan E
Format Patent
LanguageEnglish
French
Published 19.10.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A bispecific monoclonal antibody that specifically binds two distinct epitopes of the Ebola virus (EBOV) glycoprotein (GP) is described. The bispecific antibody is comprised of the antigen binding domains of GP-specific monoclonal antibodies mAb114 and S1-4-A09 ("A09"). The EBOV GP bispecific monoclonal antibody (mAb114xA09 or BiSp107) exhibits synergistic neutralization of pseudotyped virus expressing EBOV GP compared with the neutralization capacity of the combination of the individual parental antibodies. Methods for pre- and post-exposure prophylaxis and treatment are described. L'invention concerne un anticorps monoclonal bispécifique qui se lie de manière spécifique à deux épitopes distincts de la glycoprotéine (GP) du virus Ebola (EBOV). L'anticorps bispécifique est constitué des domaines de liaison à l'antigène d'anticorps monoclonaux spécifiques de GP mAb114 et S1-4-A09 ("A09"). L'anticorps monoclonal bispécifique GP EBOV (mAb114xA09 ou BiSp107) présente une neutralisation synergique du virus pseudotypé exprimant GP EBOV par comparaison avec la capacité de neutralisation de la combinaison des anticorps parentaux individuels. L'invention concerne également des méthodes de prophylaxie et de traitement pré- et post-exposition.
Bibliography:Application Number: WO2023US65775